Download PDF
CC BY 4.0 · World J Nucl Med 2023; 22(04): 316-320
DOI: 10.1055/s-0043-1777697
Case Report

Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment

Ismaheel O. Lawal 
1   Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States
2   Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
,
Mehmet A. Bilen
3   Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
,
Raghuveer K. Halkar
1   Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States
,
Ashesh B. Jani
4   Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
,
David M. Schuster
1   Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Skeletal metastases due to prostate cancer (PCa) are more commonly osteoblastic than osteolytic. In the rarer cases of osteolytic skeletal metastasis of PCa, transition to osteoblastic phenotype occurs following treatment, which indicates successful healing. In this report, we present a case of spontaneous osteolytic to osteoblastic evolution of PCa skeletal metastasis without treatment in a patient with recurrence of PCa. Our patient is a 59-year-old male who had a robotic radical prostatectomy in July 2014 for a T2c adenocarcinoma of the prostate gland (Gleason score = 4 + 3). He had adjuvant pelvic radiotherapy in January 2015 due to prostate-specific antigen (PSA) persistence. PSA began to rise in October 2015. An 18F-fluciclovine positron emission tomography/computed tomography (PET/CT) scan obtained in June 2017 at a PSA of 0.5 ng/mL was negative. Repeat 18F-fluciclovine PET/CT of February 2020 at PSA of 3.72 ng/mL showed prostate bed recurrence and a nonavid osteolytic left inferior pubic ramus lesion. 18F radiohybrid prostate-specific membrane antigen (18F-rhPSMA) PET/CT scan of August 2020 performed as part of an ongoing clinical trial confirmed local prostate bed recurrence with a low-grade radiotracer uptake in the osteolytic left inferior pubic ramus bone lesion. Without salvage therapy, 18F-fluciclovine PET/CT of October 2020 and March 2022 shows progressive sclerosis in the left pubic ramus lesion. An osteolytic to osteoblastic transition of a bone lesion as shown in this patient calls for a rethink in our understanding of untreated PCa skeletal metastasis progression. This case provides novel insight into the understanding of the temporal evolution of skeletal metastasis and calls for further research.

Keywords

18F-fluciclovine PET/CT - 18F-rhPSMA PET/CT - prostate cancer - biochemical recurrence - skeletal metastasis progression

Authors' Contributions

Ismaheel Lawal contributed to conception and design, acquisition of data, drafting of the initial manuscript, agreed to be accountable for all aspects of the work, and approved the final submitted version of the manuscript. Mehmet Bilen helped in conception and design, critical review of the manuscript for intellectual content, and approved the final submitted version of the manuscript. Raghuveer Halkar, Ashesh Jani, and David Schuster contributed to conception and design, critical review of the manuscript for intellectual content, agreed to be accountable for all aspects of the work, and approved the final submitted version of the manuscript.


Ethics Approval and Informed Consent

Consent for publication was obtained from the patient and investigations were conducted in line with the principles detailed by the 1964 Declaration of Helsinki.




Publication History

Article published online:
26 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Eastham JA, Auffenberg GB, Barocas DA. et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol 2022; 208 (01) 10-18
    CrossrefPubMedGoogle Scholar
  • 2 Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172 (03) 910-914
    CrossrefPubMedGoogle Scholar
  • 3 Tilki D, Chen MH, Wu J. et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol 2023; 41 (13) 2428-2435
    CrossrefPubMedGoogle Scholar
  • 4 Ono M, Oka S, Okudaira H. et al. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nucl Med Biol 2015; 42 (11) 887-892
    CrossrefPubMedGoogle Scholar
  • 5 Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82 (11) 2256-2261
    CrossrefPubMedGoogle Scholar
  • 6 Cerci JJ, Fanti S, Lobato EE. et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med 2022; 63 (02) 240-247
    CrossrefPubMedGoogle Scholar
  • 7 Odewole OA, Tade FI, Nieh PT. et al. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging 2016; 43 (10) 1773-1783
    CrossrefPubMedGoogle Scholar
  • 8 Emmett L, Tang R, Nandurkar R. et al. 3-Year freedom from progression after 68Ga-PSMA PET/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med 2020; 61 (06) 866-872
    CrossrefPubMedGoogle Scholar
  • 9 Jani AB, Schreibmann E, Goyal S. et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet 2021; 397 (10288): 1895-1904
    CrossrefPubMedGoogle Scholar
  • 10 Lawal IO, Lengana T, Popoola GO. et al. Pattern of prostate cancer recurrence assessed by 68Ga-PSMA-11 PET/CT in men treated with primary local therapy. J Clin Med 2021; 10 (17) 3883
    CrossrefPubMedGoogle Scholar
  • 11 Morris MJ, Rowe SP, Gorin MA. et al; CONDOR Study Group. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 2021; 27 (13) 3674-3682
    CrossrefPubMedGoogle Scholar
  • 12 Jani AB, Ravizzini GC, Gartrell BA. et al. Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol 2023
    PubMedGoogle Scholar
  • 13 Minamimoto R, Loening A, Jamali M. et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med 2015; 56 (12) 1862-1868
    CrossrefPubMedGoogle Scholar
  • 14 Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med 2007; 20 (01) 103-111
    PubMedGoogle Scholar
  • 15 Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010; 116 (06) 1406-1418
    CrossrefPubMedGoogle Scholar
  • 16 Yonou H, Ochiai A, Goya M. et al. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004; 58 (04) 406-413
    CrossrefPubMedGoogle Scholar
  • 17 Goya M, Ishii G, Miyamoto S. et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 2006; 66 (15) 1573-1584
    CrossrefPubMedGoogle Scholar
  • 18 Abiodun-Ojo OA, Jani AB, Akintayo AA. et al. Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on 18F-fluciclovine PET/CT guidance. J Nucl Med 2021; 62 (08) 1089-1096
    CrossrefPubMedGoogle Scholar
  • 19 Lawal IO, Jani AB, Adediran OA. et al. Differences in failure-free survival after salvage radiotherapy guided by conventional imaging versus 18F-fluciclovine PET/CT in postprostatectomy patients: a post hoc substratification analysis of the EMPIRE-1 trial. J Nucl Med 2023; 64 (04) 586-591
    CrossrefPubMedGoogle Scholar
  • 20 Chu CE, Alshalalfa M, Sjöström M. et al. Prostate-specific membrane antigen and fluciclovine transporter genes are associated with variable clinical features and molecular subtypes of primary prostate cancer. Eur Urol 2021; 79 (06) 717-721
    CrossrefPubMedGoogle Scholar
  • 21 Kushchayeva YS, Kushchayev SV, Glushko TY. et al. Fibrous dysplasia for radiologists: beyond ground glass bone matrix. Insights Imaging 2018; 9 (06) 1035-1056
    CrossrefPubMedGoogle Scholar